Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ine Moors

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Trials|February 16, 2024
Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: a randomized, controlled clinical trialGlenn Van Wynsberge, Veerle Grootaert, Franky Buyle, et al.
Psycho-Oncology|September 22, 2022
Identification of the most important factors related to people with cancer starting a palliative care conversation: A survey studyAnne-Lore Scherrens, Kim Beernaert, Luc Deliens, et al.
Haematologica|March 28, 2024
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexiaSarah A Pötgens, Violaine Havelange, Sophie Lecop, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2024
Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) TrialHanne Lamberink, Sammy Huygens, Robina Aerts, et al.
Blood Vessels, Thrombosis & Hemostasis|August 6, 2025
Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumabDaan Dierickx, Thierry Connerotte, Julie Dallemagne, et al.
Journal of Clinical Microbiology|January 21, 2025
Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological diseaseHanne Lamberink, Sammy Huygens, Robina Aerts, et al.
Journal of Clinical Microbiology|March 25, 2025
Correction for Lamberink et al., "Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease"Hanne Lamberink, Sammy Huygens, Robina Aerts, et al.
Haematologica|August 3, 2019
TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartmentBarbara Depreter, Karin E Weening, Karl Vandepoele, et al.
Blood Advances|January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trialGail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Trials|February 16, 2024
Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: a randomized, controlled clinical trialGlenn Van Wynsberge, Veerle Grootaert, Franky Buyle, et al.
Psycho-Oncology|September 22, 2022
Identification of the most important factors related to people with cancer starting a palliative care conversation: A survey studyAnne-Lore Scherrens, Kim Beernaert, Luc Deliens, et al.
Haematologica|March 28, 2024
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexiaSarah A Pötgens, Violaine Havelange, Sophie Lecop, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2024
Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) TrialHanne Lamberink, Sammy Huygens, Robina Aerts, et al.
Blood Vessels, Thrombosis & Hemostasis|August 6, 2025
Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumabDaan Dierickx, Thierry Connerotte, Julie Dallemagne, et al.
Journal of Clinical Microbiology|January 21, 2025
Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological diseaseHanne Lamberink, Sammy Huygens, Robina Aerts, et al.
Journal of Clinical Microbiology|March 25, 2025
Correction for Lamberink et al., "Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease"Hanne Lamberink, Sammy Huygens, Robina Aerts, et al.
Haematologica|August 3, 2019
TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartmentBarbara Depreter, Karin E Weening, Karl Vandepoele, et al.
Blood Advances|January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trialGail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
Pageof 3